Method for the generation of neural progenitor cells

• US 20070020608A1
• Filed: 05/10/2004
• Published: 01/25/2007
• Est. Priority Date: 05/08/2003
• Status: Abandoned Application

• Current Assignee: Cellartis AB
• Original Assignee: Cellartis AB
• Inventors: Eriksson, Peter, Kilmare, Eva Karin, Enerback, Sven, Zetterstrom, Mathilda
• Application Number:
  US10/555,306
• Publication Number:
  US 20070020608A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0623 Stem cells
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/5058 Neurological cells

Abstract

A rapid, simple and efficient method for the generation of neural progenitor cells from pluripotent/undifferentiated human blastocyst-derived stem (hBS) cells, neural progenitor cells obtained by the method and further differentiation of these cells into the three neural cell lineages, and the use of the neural progenitor cells and the differentiated cells in the preparation of medicaments. An important feature of the method is that neural progenitor cells are produced without a step involving formation of embryoid bodies (EB), improving the efficiency and the reducing the time for generation as compared to known methods.

Claims

1. A method for obtaining neural progenitor cells, the method comprising the steps of:

i) dissociation of undifferentiated hBS cells by enzymatic and/or by mechanical treatment to obtain hBS cell aggregates or a mixture of hBS cell aggregates and single cells,

ii) seeding the hBS cells from step i) in a growth medium on a support substrate, iii) culturing the hBS cells seeded as in step ii),

iv) optionally, replacing a part of the growth medium with a growth medium,

v) passaging the obtained cells from step iii) or iv) to obtain neural progenitor cells vi) optionally, seeding the cells from step v) on a support substrate in a growth medium,

vii) optionally, repeating step v) and/or vi) at least 1 time.

2. A method according to claim 1, wherein the neural progenitor cells are produced without a step involving formation of embryoid bodies.

4. A method according to claim 1, wherein the hBS cell are propagated on feeder cells prior to step i).

5. A method according to claim 1, wherein the hBS cells are propagated in a feeder-free culture system prior to step i).

7. A method according to claim 1, wherein the hBS cells employed in step i) have at least one of the following properties:

i) exhibit proliferation capacity in an undifferentiated state for more than 12 months when grown on mitotically inactivated embryonic feeder cells or under feeder free growth conditions,

ii) exhibit normal euploid chromosomal karyotype, and

iii) maintain potential to develop into derivatives of all types of germ layers both in vitro and in vivo,

iv) exhibit at least two of the following markers OCT-4, alkaline phosphatase, the carbohydrate epitopes SSEA-3, SSEA-4, TRA 1-60, TRA 1-81, and the protein core of a keratin sulfate/chondroitin sulfate pericellular matrix proteinglycan recognized by the monoclonal antibody GCTM-2,

v) do not exhibit molecular marker SSEA-1 or other differentiation markers, and vi) retain their pluripotency and forms teratomas in vivo when injected into immunocompromised mice,

vii) are capable of differentiation.

8. A method according to claim 7, wherein the hBS cells have the properties i)-vii).

9. A method according to claim 1, wherein the dissociation of hBS cells in step i) is performed by enzymatic treatment.

10. A method according to claim 9, wherein the dissociation of hBS cells in step i) is performed by a collagenase.

11. A method according to claim 9, wherein the dissociation of hBS cells is performed by treating hBS cells with 200 U/ml collagenase at 37°

C. from about 5 minutes to about 40 minutes.

12. A method according to claim 1, wherein the size of the cell aggregates obtained in step i) is from about 5 cells to about 200 cells.

13. A method according to claim 1, wherein the number of cells seeded on the support substrate is from about 40 000 cell/cm² to about 200 000 cell/cm².

14. A method according to claim 1, wherein the support substrate comprises an extracellular matrix component.

15. A method according to claim 1, wherein the support substrate comprises one or more substances selected from the group consisting of gelatin, laminin, polyornithine, fibronectin, Matrigel™

, agarose, poly-L-lysine, poly-D-lysine and collagen type I.

16. A method according to claim 1, wherein the support substrate comprises gelatin.

17. A method according to claim 16, wherein the concentration of gelatin is from about 0.001% (w/v) to about 0.2% (w/v).

18. A method according to claim 1, wherein the growth medium is selected from the group consisting of hBS cell medium, VitroHES™

-medium, neural cell medium, Neurobasal™

media and DMEM/F12 based medias including supplementation with B27 supplement and/or N2 supplement.

19. A method according to claim 1, wherein the growth medium is hBS cell medium or VitroHES™

-medium.

20. A method according to claim 1, wherein the growth medium has been conditioned by feeder cells.

21. A method according to claim 1, wherein the growth medium employed in the different steps of the method are the same or different.

22. A method according to claim 1, wherein the growth medium comprises one or more growth factors.

23. A method according to claim 22, wherein the one or more growth factors are FGF and/or EGF.

24. A method according to claim 22, wherein the growth factor is FGF, such as, e.g. FGF-2 or hFGF.

25. A method according to claim 23, wherein the concentration of FGF and/or EGF is from about 1 ng/ml to about 40 ng/ml.

26. A method according to claim 1, wherein the culturing is preformed at 37°

C., 5% CO₂ and 95% humidity.

27. A method according to claim 1, wherein the culturing in step iii) is performed for about 6 to 10 days.

28. A method according to claim 1, wherein the culturing in step iii) is performed for no longer than 8 days.

29. A method according to claim 1, wherein step iv) is included.

30. A method according to claim 29, wherein the growth medium from step ii) at least partly is replaced with fresh medium in step iv).

31. A method according to claim 30, wherein the part of the growth medium replaced in step iv) is from about 10% to about 100% v/v.

32. A method according to claim 30, wherein the fresh growth medium in step iv) may be the same or different to the growth medium from step ii).

33. A method according to claim 29, wherein step iv) is performed after at least 1 day of culture in step iii).

34. A method according to claim 1, wherein step v) includes mechanical or enzymatic treatment of the cells obtained from step iii) or, if relevant, step iv) and further culturing in a growth medium and on a support substrate.

35. A method according to claim 34, wherein the growth medium is the same or different as that used in step ii) and/or, if relevant, step iv).

36. A method according to claim 34, wherein the support medium is the same or different as that used in step ii) and/or, if relevant, step iv).

37. A method according to claim 1 including step vi).

38. A method according to claim 1 including step vii).

39. A method according to claim 1, wherein the progenitors obtained are viable after having been frozen and thawed.

40. A method according to claim 37, wherein step v) is repeated from about 1 to about 30 times.

41. A method according to claim 37, wherein step v) is repeated every 3-6 days.

42. A method according to claim 37, wherein step v) is repeated at about 60-90% confluence.

43. A method according to claim 37, wherein the cells obtained in step v) are grown as a monolayer.

44. A method according to claim 1, wherein the cells obtained have the following properties:

a) exhibit at least one of the following markers nestin, internextin, PSA-NCAM (or PS-NCAM or NCAM), Musashi-1, GAP-43, Cystatin C, Vimentin, A2B5, AC1 33, ATF5, Sox-2 and PAX-6,

b) are capable of differentiating,

c) are capable of self renewal.

45. A method according to claim 1, wherein the majority of cells obtained do not exhibit one or more markers for undifferentiated hBS cells.

46. A method according to claim 45, wherein the markers for undifferentiated hBS cells are selected from the group consisting of SSEA-3, SSEA-4, GCTM-2, Tra-1-60, Tra-1-80, Oct-4, Cripto, Rex-1 or FGF4.

47. A method according to claim 1, wherein the majority of cells obtained do not exhibit one or more markers for the endoderm germ layer, such as, e.g., alfa-fetoprotein or HNF3-α

.

48. A method according to claim 1, wherein the majority of cells obtained do not exhibit one or more markers for the mesoderm germ layer, such as, e.g., cardiac troponin 1, Brachyury or Desmin.

49. A method according to claim 1, wherein the majority of cells obtained do not exhibit markers for mature neuronal cells, such as, e.g., β

-III-Tubulin, MAP2, NF-L, NF-H, NF200, NF68, DoubleCortin, ChAT, DDC, GABA, DBH, NSE, synaptophysin, TH, Nurr-1, NeuN, glutamate or serotonin.

50. A method according to claim 1, wherein the majority of cells obtained do not exhibit one or more markers for glial cells, such as, e.g., GFAP, S-100, GaIC, RIP.

51. A method according to claim 45, wherein the majority of cells corresponds to 80% of more of the cells.

52. A method according to claim 45, wherein the cells are obtained from step v) or, if relevant, from step vi).

53. A method according to claim 1, wherein the cells obtained are further differentiated into at least one of the three neural cell lineages, e.g., astrocytes, oligodendrocytes and neurons.

54. A method according to claim 53, wherein the differentiated cells display the expression of at least one of the neuronal or glial cell type markers selected from the group consisting of β

-III tubulin (TUJ1), NeuN, DoubleCortin, tyrosine hydroxylase, Map 2, NF-L, NH-H, NSE, DBH, GABA, synaptophysin, glutamate, serotonin, Nurr-1, NF200, NF68, GFAP, GaIC and RIP.

55. A method according to claim 53, wherein the differentiated cells display the expression of at least one of the oligodendrocyte cell type markers RIP or GaIC.

56. A method according to claim 53, wherein the differentiated cells display the expression of at least one of the astrocyte cell type markers GFAP or S-100.

57. A method for studying early neurogenesis wherein the neural progenitor cells obtained in claim 1 are used as an in vitro model.

58. A method for studying human neurodegenerative disorders wherein neural progenitor cells obtained in claim 1 are used as an in vitro model.

59. A screening method comprising utilizing neural progenitor cells obtained in claim 1.

60. An in vitro method for toxicity screening comprising utilizing neural progenitor cells obtained in claim 1.

61. An in vitro method for screening of potential drug substances comprising utilizing neural progenitor cells obtained in claim 1.

62. A method for the identification of potential drug substances comprising utilizing neural progenitor cells obtained in claim 1.

63. A medicine comprising an effective concentration of neural progenitor cells obtained in claim 1.

64. A medicament for the prevention and/or treatment of pathologies or diseases caused by tissue degeneration comprising an effective concentration of neural progenitor cells obtained in claim 1.

65. A medicament according to claim 64 wherein the tissue degeneration is degeneration of neural tissue.

66. A medicament for the prevention or treatment of pathologies and/or diseases in the nervous system comprising an effective concentration of neural progenitor cells obtained in claim 1.

67. A medicament according to claim 66, wherein the pathologies and/or diseases are selected from the group consisting of multiple schlerosis, spinal chord injury, encephalopathies, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, Huntingdon'"'"'s disease, stroke, traumatic brain injuries, hypoxia induced brain injuries, ischemia induced brain injuries, hypoglycemic brain injuries, degenerative disorders of the nervous system, brain tumours and neuropathies in the peripheral nervous system.

68. A medicine according to claim 63 which comprises neural progenitor cells dispersed in a pharmaceutically acceptable medium.

69. A medicine according to claim 68, wherein the medium is an aqueous medium.

70. A medicine according to claim 68 further comprising one or more additives selected from the group consisting of pH adjusting agents, stabilizers, preservatives, osmotic pressure adjusting agents, and physiologically acceptable salts.

71. A medicine according to claim 68 further comprising one or more agents selected from the group consisting of therapeutically active substances, prophylactically active substances, engraftment improving agents, viability improving agents, differentiation improving agent and immunosuppressive agents.

72. A composition comprising neural progenitor cells obtained by the method of claim 1.

73. A composition according to claim 72, wherein the amount of neural progenitor cells is at least 50% of the total cell population.

74. An essentially pure preparation of neural progenitor cells, obtained by the method according to claim 1, wherein the cells display the expression of at least one of the following neural progenitor cell type markers nestin, internextin, PSAN-CAM (or NCAM), Musashi-1, GAP-43, Cystatin C, Vimentin, A2B5, AC133, ATF5, HSA Sox-2 or PAX-6 and wherein the cells do not display expression of one or more markers for cell types from other germ layers.

3. (canceled)

6. (canceled)